Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Importance and Determinants of Comorbidities, Functional Limitations and Multiple Myeloma (MM)-Specific Risk Factors: Further Development of an Improved and Weighted MM-Risk Score (Freiburg Comorbidity Index [FCI])

Anne-Saskia Domm, Stefanie Hieke, Gabriele Ihorst, Milena Pantic, Bernd Koch, Martina Kleber, MD, Johannes Waldschmidt, MD, Martin Schumacher, PhD, Ralph Wäsch, MD, Monika Engelhardt, MD

Blood (2014) 124 (21): 733.

https://doi.org/10.1182/blood.V124.21.733.733

Published: 2014

Journal Articles

Second Malignant Neoplasms Following Multiple Myeloma: A Cohort Study On 744 Patients Treated 1997-2011

Martina Kleber, Kerstin Höck, Gabriele Ihorst, Bernd Koch, Ralph Waesch, MD, Ola Landgren, MD, PhD, Monika Engelhardt, MD

Blood (2013) 122 (21): 3100.

https://doi.org/10.1182/blood.V122.21.3100.3100

Published: 2013

Journal Articles

Estimation Of GFR With Different EGFR Equations In Multiple Myeloma Patients Receiving Lenalidomide Treatment

Martina Kleber, Bernd Koch, Ralph Waesch, MD, Monika Engelhardt, MD

Blood (2013) 122 (21): 5324.

https://doi.org/10.1182/blood.V122.21.5324.5324

Published: 2013

Journal Articles

Individual Patient Data Of Conditional Survival Analysis In a Large Cohort Of 816 Multiple Myeloma (MM) Patients Constitutes a Different Way To Identify Patients With Extended Life Expectancy

Martina Kleber, Stefanie Hieke, Milena Pantic, Bernd Koch, Gabriele Ihorst, Ralph Waesch, MD, Philippe Moreau, MD, Martin Schumacher, Monika Engelhardt, MD

Blood (2013) 122 (21): 1745.

https://doi.org/10.1182/blood.V122.21.1745.1745

Published: 2013

Journal Articles

Conditional Survival Analysis in a Large Cohort of Multiple Myeloma Patients Provides Detailed Information about Long-Term Survival and Constitutes a Different Way to Identify Patients with Extended Life Expectancy

Martina Kleber, Stefanie Hieke, Bernd Koch, Gabriele Ihorst, Ralph Wäsch, Martin Schumacher, Monika Engelhardt

Blood (2012) 120 (21): 4982.

https://doi.org/10.1182/blood.V120.21.4982.4982

Published: 2012

Journal Articles

Risks for Different Neoplasms (DNs) in Multiple Myeloma (MM) Patients May Involve Specific Host-, Myeloma- and Treatment-Related Susceptibilities: Registry Data of 681 Consecutive MM Patients,

Martina Kleber, Kerstin Höck, Gabriele Ihorst, Bernd Koch, Ralph Waesch, MD, Monika Engelhardt, MD

Blood (2011) 118 (21): 3929.

https://doi.org/10.1182/blood.V118.21.3929.3929

Published: 2011

Journal Articles

Use of Lenalidomide May Surmount the Adverse Prognosis Induced by Renal Impairment In Patients (pts) with Relapsed/Refractory Multiple Myeloma (MM)

Martina Kleber, Gabriele Ihorst, Josefina Udi, Bernd Koch, Monika Engelhardt

Blood (2010) 116 (21): 3042.

https://doi.org/10.1182/blood.V116.21.3042.3042

Published: 2010

Journal Articles

Sensitive Detection of Renal Function in Multiple Myeloma (MM) Patients (pts) Via Estimated Glomerular Filtration Rate (eGFR) Unmasks Manifest Renal Function in Pts Receiving Lenalidomide and Suggests to Serve as An Additional Predictive Tool of Treatment Response.

Martina Kleber, MD, Peter Haas, Bernd Koch, Manuela Burbeck, Monika Engelhardt

Blood (2009) 114 (22): 4945.

https://doi.org/10.1182/blood.V114.22.4945.4945

Published: 2009

Journal Articles

Detection of Renal Impairment (RI) as One Specific Comorbidity Factor in Multiple Myeloma (MM) Patients: Multi-Center Study in 198 Consecutive Patients

Martina Kleber, Gabriele Ihorst, Barbara Deschler, Christian Jakob, MD, Peter Liebisch, Bernd Koch, Orhan Sezer, Monika Engelhardt

Blood (2008) 112 (11): 2372.

https://doi.org/10.1182/blood.V112.11.2372.2372

Published: 2008

Journal Articles

A Multi-Center Analysis of Renal Impairment as a Potential Prognostic Factor: Analysis in Multiple Myeloma Patients Treated with Standard or High-Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation.

Martina Kleber, MD, Gabriele Ihorst, PhD, Christian Jakob, MD, Peter Liebisch, MD, Bernd Koch, PhD, Monika Engelhardt, MD

Blood (2007) 110 (11): 4830.

https://doi.org/10.1182/blood.V110.11.4830.4830

Published: 2007

Journal Articles

Improved Prediction of Kidney Disease by Estimating Renal Function: Use in Multiple Myeloma Patients Treated with Standard Versus High-Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation.

Martina Kleber, MD, Truc Ngo, MD, Gabriele Ihorst, Bernd Koch, Monika Engelhardt, MD

Blood (2006) 108 (11): 5497.

https://doi.org/10.1182/blood.V108.11.5497.5497

Published: 2006

Journal Articles

Mild Renal Impairment as a Potential Prognostic Factor in Patients with Solid Tumors and Hematological Malignancies.

Martina Kleber, MD, Kris Bauchmüller, Gabriele Ihorst, Bernd Koch, Monika Engelhardt, MD

Blood (2005) 106 (11): 2250.

https://doi.org/10.1182/blood.V106.11.2250.2250

Published: 2005

NARROW

Importance and Determinants of Comorbidities, Functional Limitations and Multiple Myeloma (MM)-Specific Risk Factors: Further Development of an Improved and Weighted MM-Risk Score (Freiburg Comorbidity Index [FCI])

Second Malignant Neoplasms Following Multiple Myeloma: A Cohort Study On 744 Patients Treated 1997-2011

Estimation Of GFR With Different EGFR Equations In Multiple Myeloma Patients Receiving Lenalidomide Treatment

Individual Patient Data Of Conditional Survival Analysis In a Large Cohort Of 816 Multiple Myeloma (MM) Patients Constitutes a Different Way To Identify Patients With Extended Life Expectancy

Conditional Survival Analysis in a Large Cohort of Multiple Myeloma Patients Provides Detailed Information about Long-Term Survival and Constitutes a Different Way to Identify Patients with Extended Life Expectancy

Risks for Different Neoplasms (DNs) in Multiple Myeloma (MM) Patients May Involve Specific Host-, Myeloma- and Treatment-Related Susceptibilities: Registry Data of 681 Consecutive MM Patients,

Use of Lenalidomide May Surmount the Adverse Prognosis Induced by Renal Impairment In Patients (pts) with Relapsed/Refractory Multiple Myeloma (MM)

Sensitive Detection of Renal Function in Multiple Myeloma (MM) Patients (pts) Via Estimated Glomerular Filtration Rate (eGFR) Unmasks Manifest Renal Function in Pts Receiving Lenalidomide and Suggests to Serve as An Additional Predictive Tool of Treatment Response.

Detection of Renal Impairment (RI) as One Specific Comorbidity Factor in Multiple Myeloma (MM) Patients: Multi-Center Study in 198 Consecutive Patients

A Multi-Center Analysis of Renal Impairment as a Potential Prognostic Factor: Analysis in Multiple Myeloma Patients Treated with Standard or High-Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation.

Improved Prediction of Kidney Disease by Estimating Renal Function: Use in Multiple Myeloma Patients Treated with Standard Versus High-Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation.

Mild Renal Impairment as a Potential Prognostic Factor in Patients with Solid Tumors and Hematological Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only